Celltrion, Inc.
068270
주식 순위
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
주가
$146.63
시가총액
$33.44B
변동 (1일)
-1.52%
변동 (1년)
23.60%
국가
KR
거래 Celltrion, Inc. (068270)
카테고리
Healthcare
Celltrion, Inc. (068270)의 수익
Jun 2026 기준 수익 TTM: $1.35B
Celltrion, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $1.35B입니다. 2024년에 회사는 $391.87M의 수익을 올렸으며 이는 2023년의 수익 $518.41M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Celltrion, Inc.의 수익 기록 (2007 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.35B | 69.43% |
| 2025 | $798.62M | 103.80% |
| 2024 | $391.87M | -24.41% |
| 2023 | $518.41M | 4.47% |
| 2022 | $496.21M | -20.13% |
| 2021 | $621.28M | 2.64% |
| 2020 | $605.31M | 82.96% |
| 2019 | $330.83M | 22.13% |
| 2018 | $270.89M | -40.24% |
| 2017 | $453.27M | 138.31% |
| 2016 | $190.20M | 37.04% |
| 2015 | $138.79M | 1.86% |
| 2014 | $136.26M | 24.03% |
| 2013 | $109.86M | -37.65% |
| 2012 | $176.20M | 11.36% |
| 2011 | $158.22M | 61.51% |
| 2010 | $97.97M | 71.21% |
| 2009 | $57.22M | 319.20% |
| 2008 | $13.65M | 4,681.03% |
| 2007 | $285.51K | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 289.84% |
US
|
|
| $-3.09B | -328.14% |
US
|
|
| $-4.02B | -396.82% |
AU
|
|
| $2.85B | 110.31% |
BE
|
|
| $1.95B | 44.16% |
NL
|
